186 related articles for article (PubMed ID: 24956110)
1. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.
Dietrich J; Andreasen LV; Andersen P; Agger EM
PLoS One; 2014; 9(6):e100879. PubMed ID: 24956110
[TBL] [Abstract][Full Text] [Related]
2. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.
Andreasen LV; Hansen LB; Andersen P; Agger EM; Dietrich J
Vaccine; 2015 Apr; 33(15):1873-9. PubMed ID: 25698487
[TBL] [Abstract][Full Text] [Related]
3. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
[TBL] [Abstract][Full Text] [Related]
4. Intranasal and sublingual delivery of inactivated polio vaccine.
Kraan H; Soema P; Amorij JP; Kersten G
Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.
Troy SB; Kouiavskaia D; Siik J; Kochba E; Beydoun H; Mirochnitchenko O; Levin Y; Khardori N; Chumakov K; Maldonado Y
J Infect Dis; 2015 Jun; 211(12):1969-76. PubMed ID: 25567841
[TBL] [Abstract][Full Text] [Related]
8. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.
Westdijk J; Koedam P; Barro M; Steil BP; Collin N; Vedvick TS; Bakker WA; van der Ley P; Kersten G
Vaccine; 2013 Feb; 31(9):1298-304. PubMed ID: 23313617
[TBL] [Abstract][Full Text] [Related]
9. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.
Wang Y; Zade J; Moon SS; Weldon W; Pisal SS; Glass RI; Dhere RM; Jiang B
Vaccine; 2019 Jan; 37(5):698-704. PubMed ID: 30626530
[TBL] [Abstract][Full Text] [Related]
10. Intradermal fractional dose inactivated polio vaccine: a review of the literature.
Nelson KS; Janssen JM; Troy SB; Maldonado Y
Vaccine; 2012 Jan; 30(2):121-5. PubMed ID: 22100886
[TBL] [Abstract][Full Text] [Related]
11. Alternative inactivated poliovirus vaccines adjuvanted with Quillaja brasiliensis or Quil-a saponins are equally effective in inducing specific immune responses.
de Costa F; Yendo AC; Cibulski SP; Fleck JD; Roehe PM; Spilki FR; Gosmann G; Fett-Neto AG
PLoS One; 2014; 9(8):e105374. PubMed ID: 25148077
[TBL] [Abstract][Full Text] [Related]
12. A mucosal adjuvant for the inactivated poliovirus vaccine.
Steil BP; Jorquera P; Westdijk J; Bakker WA; Johnston RE; Barro M
Vaccine; 2014 Jan; 32(5):558-63. PubMed ID: 24333345
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
14. Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.
Schipper P; van der Maaden K; Romeijn S; Oomens C; Kersten G; Jiskoot W; Bouwstra J
Pharm Res; 2016 Sep; 33(9):2269-79. PubMed ID: 27317570
[TBL] [Abstract][Full Text] [Related]
15. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity study to investigate the interchangeability among three different types of polio vaccine: A cohort study in Japan.
Ohfuji S; Ito K; Ishibashi M; Shindo S; Takasaki Y; Yokoyama T; Yokoyama T; Yamashita Y; Shibao K; Nakano T; Tsuru T; Irie S; Hirota Y
Medicine (Baltimore); 2017 Jun; 96(23):e7073. PubMed ID: 28591046
[TBL] [Abstract][Full Text] [Related]
18. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
19. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM
Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946
[TBL] [Abstract][Full Text] [Related]
20. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.
Bandyopadhyay AS; Asturias EJ; O'Ryan M; Oberste MS; Weldon W; Clemens R; Rüttimann R; Modlin JF; Gast C
Vaccine; 2017 Dec; 35(52):7283-7291. PubMed ID: 29150209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
